Members of the division are actively engaged in both basic and clinical grant-supported research.

Basic Research

Veronica M. Catanese M.D.
Dr. Catanese's laboratory is engaged in investigation of the pathogenesis of HIV protease-inhibitor associated lipodystrophy and hyperlipidemia using both molecular, biological and clinical/translational approaches.

David L. Kleinberg M.D.
Dr. Kleinberg's laboratory has a long-standing and productive interest in control of mammary gland development.

David Ron M.D.
Dr. Ron's work is focused on the cellular response to proteotoxic stress, and the impact of malfolded proteins on diseases such as type 2 diabetes.

Herbert H. Samuels M.D.
Dr. Samuels' laboratory is nationally and internationally recognized for its investigation of the mechanism of action of thyroid hormone, and conserved elements of gene regulation by members of the nuclear hormone receptor superfamily.

Clinical Investigations

Veronica M. Catanese M.D.
Dr. Catanese's group is conducting a pilot study designed to assess the effects of thiazolidinediones (and activation of the PPAR-gamma nuclear receptor system) on protease-inhibitor-associated hypertriglyceridemia.

Dr. Ann Danoff
Dr. Dannoff is a co-investigator on the NIH Women's Interagency HIV Study (investigating HIV-associated metabolic dysfunction), and also collaborates with Dr. Kleinberg.

David L. Kleinberg M.D.
Dr. Kleinberg has been engaged for several years in multiple investigator-initiated single and multicenter studies evaluating new methods for detecting and treating acromegaly and adult GH deficiency.

Dr. Stephen Richardson
Dr. Richardson serves as principal investigator on several multicenter studies on newer therapies for type 2 diabetes and macrovascular disease in patients with type 2 diabetes and insulin resistance.